Verquvo (vericiguat) / Bayer, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 2 Diseases   27 Trials   27 Trials   1089 News 


«12...45678910111213141516»
  • ||||||||||  vericiguat (BAY 1021189) / Bayer, Merck (MSD)
    [VIRTUAL] Effect Of Vericiguat In Victoria According To Guideline-directed Medical Therapy (Scientific Session Theater C) -  Sep 17, 2020 - Abstract #HFSA2020HFSA_862;    
    There is no abstract associated with this presentation. Patients in VICTORIA were well treated with GDMT and the efficacy of vericiguat was consistent across background GDMT therapy with very high indication-corrected adherence accounting for patient-level indications, contraindications, and tolerance.
  • ||||||||||  vericiguat (BAY 1021189) / Bayer, Merck (MSD)
    [VIRTUAL] Where Does Vericiguat Fit in the Contemporary Standard of Care Management of HFrEF Care? (Scientific Session Theater A) -  Sep 17, 2020 - Abstract #HFSA2020HFSA_759;    
    Patients in VICTORIA were well treated with GDMT and the efficacy of vericiguat was consistent across background GDMT therapy with very high indication-corrected adherence accounting for patient-level indications, contraindications, and tolerance. There is no abstract associated with this presentation.
  • ||||||||||  vericiguat (BAY 1021189) / Bayer, Merck (MSD)
    [VIRTUAL] New Drugs - Dapaglifolzin, Vericiguat, Empaglifolzin (Scientific Session Theater A) -  Sep 17, 2020 - Abstract #HFSA2020HFSA_632;    
    There is no abstract associated with this presentation. There is no abstract associated with this presentation.
  • ||||||||||  vericiguat (BAY 1021189) / Bayer, Merck (MSD)
    [VIRTUAL] Index Event, Clinical Outcomes and Response to Vericiguat in the Victoria Trial (OnDemand) -  Sep 17, 2020 - Abstract #AHA2020AHA_1997;    
    Among patients with worsening chronic HF, those within a 3 month window of HFH had almost a 1.5 times risk of CV death or HFH compared to those requiring IV diuretics but not HFH, irrespective of age or clinical risk factors. Vericiguat added to standard therapy was associated with similar benefit across the spectrum of risk in worsening HF.
  • ||||||||||  vericiguat (BAY 1021189) / Bayer, Merck (MSD)
    [VIRTUAL] Effect Of Vericiguat In Victoria According To Guideline-directed Medical Therapy (Poster Hall - ePosters) -  Sep 10, 2020 - Abstract #HFSA2020HFSA_270;    
    Vericiguat added to standard therapy was associated with similar benefit across the spectrum of risk in worsening HF. Patients in VICTORIA were well treated with GDMT and the efficacy of vericiguat was consistent across background GDMT therapy with very high indication-corrected adherence accounting for patient-level indications, contraindications and tolerance.
  • ||||||||||  vericiguat (BAY 1021189) / Bayer, Merck (MSD), Adempas (riociguat) / Bayer
    [VIRTUAL] Safety And Efficacy Of Soluble Guanylate Cyclase Stimulators In Patients With Heart Failure: A Systematic Review And Meta-analysis (Poster Hall - ePosters) -  Sep 10, 2020 - Abstract #HFSA2020HFSA_159;    
    Patients in VICTORIA were well treated with GDMT and the efficacy of vericiguat was consistent across background GDMT therapy with very high indication-corrected adherence accounting for patient-level indications, contraindications and tolerance. The use of vericiguat and riociguat in conjunction with standard heart failure therapy shows no benefit in terms of decreasing HF-related hospitalizations or mortality.
  • ||||||||||  Review, Journal:  Heart Failure With Reduced Ejection Fraction: A Review. (Pubmed Central) -  Aug 19, 2020   
    Recent developments include SGLT2 inhibitors, vericiguat, and transcatheter mitral valve repair, all of which incrementally improve prognosis beyond foundational neurohormonal therapies. Disease morbidity and mortality remain high, with a 5-year survival rate of 25% after hospitalization for HFrEF.
  • ||||||||||  vericiguat (BAY 1021189) / Bayer, Merck (MSD)
    [VIRTUAL] Physiologically-based pharmacokinetic (PBPK) exploration of extrinsic factors influencing vericiguat pharmacokinetics () -  Jul 30, 2020 - Abstract #ESC2020ESC_584;    
    P3
    A prospective prediction of a virtual DDI trial between the UGT1A1 inhibitor atazanavir yielded an AUCR of 1.12 (geoCV 2.9%; 90% population interval: 1.07 to 1.17) and a CmaxR of 1.04 (geoCV 1.1%; 90% population interval: 1.03 to 1.06). The proposed population intervals for AUCR and CmaxR for both DDI studies lie within the default no-effect boundary of 0.80 to 1.25 according to the to January 2020 FDA DDI guideline.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Clinical, Clinical Trial,Phase III, Journal:  Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. (Pubmed Central) -  May 25, 2020   
    P3
    Among patients with high-risk heart failure, the incidence of death from cardiovascular causes or hospitalization for heart failure was lower among those who received vericiguat than among those who received placebo. (Funded by Merck Sharp & Dohme [a subsidiary of Merck] and Bayer; VICTORIA ClinicalTrials.gov number, NCT02861534.).